BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9864919)

  • 1. Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL).
    Callea V; Clò V; Morabito F; Baldini L; Stelitano C; Narni F; Avanzini P; Brugiatelli M; Silingardi V
    Haematologica; 1998 Nov; 83(11):993-7. PubMed ID: 9864919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Longo G; Fiorani C; Sacchi S; Callea V; Lombardo M; Federico M; Stelitano C; Angrilli F; Vallisa D; Gobbi PG; Ilariucci F; Frassoldati A; Petrini M; Silingardi V
    Haematologica; 1999 May; 84(5):425-30. PubMed ID: 10329921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Merli F; Federico M; Avanzini P; Ilariucci F; Stelitano C; Iannitto E; Colombi M; Vallisa D; Santagati G; Picinini L
    Haematologica; 1998 Mar; 83(3):217-21. PubMed ID: 9573675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
    Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
    Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.
    Bertini M; Rus C; Freilone R; Botto B; Calvi R; Novero D; Orsucci L; Vitolo U; Palestro G; Resegotti L
    Haematologica; 1998 Apr; 83(4):312-6. PubMed ID: 9592980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
    Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M
    Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
    Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
    Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.
    Simonelli C; Spina M; Cinelli R; Talamini R; Tedeschi R; Gloghini A; Vaccher E; Carbone A; Tirelli U
    J Clin Oncol; 2003 Nov; 21(21):3948-54. PubMed ID: 14581418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
    He YF; Zhang YJ; Li YH; Lin TY; Xia YF; Lu TX; Huang HQ; Jiang WQ; Xian CG; He YJ; Guan ZZ
    Ai Zheng; 2006 Dec; 25(12):1538-42. PubMed ID: 17166382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.